[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355530-105":59,"doc-detail-355530-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-ptch1-drug-efflux-activity-enhances-chemotherapy-efficacy-against-triple-negative-breast-cancers","Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers","","Our previous work showed PTCH1, a Hedgehog receptor, transports chemotherapeutic drugs out of cancer cells and contributes to chemotherapy resistance. PTCH1 drug efflux uses a reverse pH gradient, making it cancer-cell specific and a promising therapeutic target. Here, PTCH1 mRNA is detected in breast tumor samples and circulating tumor cells, especially in triple-negative breast cancer (TNBC), where high PTCH1 levels predict poor prognosis. PTCH1 inhibition increases cytotoxicity of doxorubicin and docetaxel in TNBC cell lines, suggesting PTCH1 efflux blockade can enhance neoadjuvant or adjuvant therapy while reducing resistance, relapse, and metastasis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-ptch1-drug-efflux-activity-enhances-chemotherapy-efficacy-against-triple-negative-breast-cancers/355530/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-ptch1-drug-efflux-activity-enhances-chemotherapy-efficacy-against-triple-negative-breast-cancers/355530.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PTCH1 play in chemotherapy resistance?","Question",{"text":112,"@type":113},"PTCH1 acts as a transporter that exports chemotherapeutic drugs from cancer cells, contributing to resistance. Its efflux activity is driven by a reverse pH gradient and is specific to cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is PTCH1 related to triple-negative breast cancer (TNBC) prognosis?",{"text":117,"@type":113},"PTCH1 mRNA is found in breast cancer tumor samples and circulating tumor cells, particularly in TNBC. Higher PTCH1 mRNA levels correlate with poor prognosis in TNBC patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the effect of inhibiting PTCH1 drug efflux on chemotherapy?",{"text":121,"@type":113},"Inhibiting PTCH1 efflux activity significantly increases the cytotoxic effects of chemotherapies such as doxorubicin and docetaxel in multiple TNBC cell lines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355530,1790695454,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Translational Oncology 68 (2026) 102777  \nContents lists available at ScienceDirect  \nTranslational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Original Research\u003Cbr>Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers\u003Cbr>Sarah Cogoluegnesa, Sandra Kovachkab, Thierry Dubois c, Roberto Würth d,e,f,\u003Cbr>Elisa Donato d,e,f, Andreas Trumppd,e,f, Michel Franco a , Fr´ed´eric Luton a, St´ephane Azoulay b, Isabelle Mus-Veteau a,* \u003Cbr>a University Cˆote d’Azur, CNRS, INSERM, IPMC, 660 route des Lucioles, Valbonne 06560, France b University Cˆote d’Azur, CNRS, ICN, 28 Avenue Valrose, 06108, Nice CEDEX 2, France\u003Cbr>c Institut Curie, PSL University, Sorbonne Universit´e, Translational Research Department, CNRS UMR144 Cell Biology and Cancer, Breast Cancer Biology Group, 26 rued’Ulm, Paris 75005, France\u003Cbr>d Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg 69120, Germany e Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg 69120, Germany f German Cancer Consortium (DKTK), Heidelberg, Germany |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: TNBC PTCH1\u003Cbr>Drug efflux Chemotherapy resistance Doxorubicin\u003Cbr>Docetaxel |  | Our previous work has revealed that PTCH1, a Hedgehog receptor which is expressed in many aggressive cancers, plays a role in transporting chemotherapeutic drugs out of cancer cells and contributes to their resistance to chemotherapy. PTCH1 transports drugs via the proton motive force using the 'reverse pH gradient', which makes its drug efflux activity specific to cancer cells and PTCH1 a highly relevant and specific new therapeutic target for cancer treatment. We have identified a small molecule produced by a marine sponge as being able to inhibit PTCH1 efflux activity and increase the efficacy of vemurafenib treatment on BRAF-mutated melanoma cells in vitro and in vivo in mice. In the present study, we demonstrate the presence of PTCH1 mRNA in tumour samples and circulating tumour cells from breast cancer patients, particularly those with triple-negative breast cancer (TNBC). TNBC is the most aggressive breast cancer subtype, characterised by a high risk of resistance to chemotherapy and a high potential for relapse. Our analyses reveal that high levels of PTCH1 mRNA are associated with a poor prognosis in TNBC patients. We found that inhibiting PTCH1 drug efflux activity significantly increased the cytotoxic effect of chemotherapies such as doxorubicin and docetaxel in three TNBC cell lines. Overall, our findings suggest that PTCH1 plays a role in the resistance of TNBC cells to chemotherapy, and that using a PTCH1 efflux inhibitor during neoadjuvant or adjuvant therapy could enhance the efficacy of treatment against PTCH1-expressing TNBC, while preventing treatment resistance, relapse, and metastasis formation. |\n\nIntroduction  \nBreast cancer (BC) is the most prevalent tumour and the leading cause of cancer-related deaths among women worldwide, with approximately 2.2 million new cases and 685,000 deaths reported globally in 2020 [1,2]. It encompasses a complex spectrum of diseases, with various genetic and molecular features contributing to tumour development and progression [3,4]. Invasive breast cancers (IBCs) are classified using histological evaluation, molecular profiling, and surrogate markers. The World Health Organization (WHO) recognises 18 distinct histological subtypes of IBC. The most common of these is invasive carcinoma of no  \nspecial type (NST), accounting for 40% to 80% of cases [5]. IBC can be subdivided into molecular subtypes: HER2-enriched, luminal A, luminal B and basal-like, based on tumour gene expression patterns. In clinical practice, surrogate markers such as oestrogen receptor (ER), proges","cbCairTcocrkqhpN","https://ap.wps.com/l/cbCairTcocrkqhpN","pdf",4562228,"English","# Introduction\n## Breast cancer background and classification\n## Triple-negative breast cancer and unmet needs\n## Chemotherapy and treatment resistance","[{\"question\":\"What role does PTCH1 play in chemotherapy resistance?\",\"answer\":\"PTCH1 acts as a transporter that exports chemotherapeutic drugs from cancer cells, contributing to resistance. Its efflux activity is driven by a reverse pH gradient and is specific to cancer cells.\"},{\"question\":\"How is PTCH1 related to triple-negative breast cancer (TNBC) prognosis?\",\"answer\":\"PTCH1 mRNA is found in breast cancer tumor samples and circulating tumor cells, particularly in TNBC. Higher PTCH1 mRNA levels correlate with poor prognosis in TNBC patients.\"},{\"question\":\"What is the effect of inhibiting PTCH1 drug efflux on chemotherapy?\",\"answer\":\"Inhibiting PTCH1 efflux activity significantly increases the cytotoxic effects of chemotherapies such as doxorubicin and docetaxel in multiple TNBC cell lines.\"}]","Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers | PDF",1790119677,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/397f8d3b8c9834c60ed194bda7ae97cc.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9616c0f630b70dffca97140cd46adf1e.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f56ecc81db8ebbef1b72a4f6194a3df3.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61409ded4cf41475dfcd2937ecf32a01.webp",980,1306]